We are pleased to announce that Megalabs has completed the acquisition of Croma’s operation in Brazil. The agreement includes distribution rights for the rest of Latin America and the Caribbean for hyaluronic acid fillers, polynucleotide injectables, Croma’s extensive portfolio of skin care products, as well as all future developments.

This acquisition strengthens our presence in Dermatology and allows us to expand throughout the region in the aesthetic dermatology market.

Dermatology, a key business field for Megalabs, starred by the product line Medihealth, available in all Latin American countries and more recently in the US with DS Labs, is the fundament for adding Croma’s portfolio which is expected to take over a relevant part in strengthening Megalabs position in the region.

Entering the aesthetic field is a big step forward, Gianclaudio Broggi, Megalabs Global CEO, is looking forward to the cooperation: “Minimally invasive treatments have seen significant growth around the world. The reduction in recovery time and the possibility of enjoying visible results from the first moment make these treatments very attractive to many patients”.

With the partnership, Croma-Pharma® is continuing its ambition to expand accessibility of their highly innovative aesthetic product portfolio, such as hyaluronic acid fillers, botulinum toxin, skin boosters, biostimulators and PDO threads, into new markets.

Andreas Prinz, CEO at Croma, comments: “We are excited to partner with Megalabs to expand our footprint in this important region. With our comprehensive portfolio, backed up by numerous clinical studies showing the safety and effectiveness of our products, we believe that the future of Megalabs and Croma-Pharma is bright.”

We wish Megalabs Brazil much success, we are confident that this strategic operation will continue to strengthen our growth in the Brazilian pharmaceutical market.

Download Document

Croma